Mihael Hristos Polymeropoulos
President and CEO at Vanda Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Vanda Pharmaceuticals Inc., 3 years.
Vanda Pharmaceuticals Inc.
Director · President and CEO
Chief executive roles
Vanda Pharmaceuticals Inc.
· President and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Vanda Pharmaceuticals Inc. | Open-market sale | −156,235 | $8.17 | $1,276,440 |
| Feb 18, 2026 | Vanda Pharmaceuticals Inc. | Grant or award | +525,000 | — | — |
| Aug 7, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +10,000 | $4.15 | $41,500 |
| May 21, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +9,519 | $4.40 | $41,884 |
| May 21, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +481 | $4.39 | $2,112 |
| May 16, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +20,000 | $4.22 | $84,400 |
| Mar 6, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +5,000 | $5.02 | $25,100 |
| Mar 6, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +5,000 | $5.01 | $25,050 |
| Mar 5, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +5,000 | $5.01 | $25,050 |
| Mar 5, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +5,000 | $5.03 | $25,150 |
| Mar 3, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +10,000 | $4.71 | $47,100 |
| Mar 1, 2025 | Vanda Pharmaceuticals Inc. | Shares withheld for tax | −95,999 | $4.76 | $456,955 |
| Feb 28, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +10,000 | $4.76 | $47,600 |
| Feb 27, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +10,000 | $4.76 | $47,600 |
| Feb 26, 2025 | Vanda Pharmaceuticals Inc. | Open-market purchase | +5,000 | $4.75 | $23,750 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.